IMPLANET announces a signature of a MOU on a worldwide partnership with Korean association LK BIOMED
Dec 07, 2017
OTC Disclosure News Service
Implanet announces a signature of a MOU on a worldwide partnership with Korean association LK BIOMED
- Complementary products operation charity breakthrough technology
- Global entrance to Asian and European markets
- Amplification of blurb means in a United States
Bordeaux, Boston, Dec 6, 2017: IMPLANET (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical record association specializing in vertebral and knee-surgery implants, announces that it has sealed a Memorandum of Understanding with a perspective to environment adult a vital partnership with Korean association LK BIOMED.
LK BIOMED is a association listed on a Kosdaq batch sell in Seoul, Korea. It designs, develops and markets an endless operation of high-end implants for spine medicine in Asia and a United States. In 2016, this fast-growing association generated sum income of 31 million dollars, including 10 million in a United States by a Aegis Spine subsidiary.
This vital partnership, that should be finalized by no after than Jan 31, 2018, provides IMPLANET with a singular event to significantly accelerate a enlargement interjection to LK BIOMEDs timeless participation in a United States and Asia.
- In a United States: IMPLANET America will join army with Aegis Spine to accelerate a selling of a Jazz® platform, quite by a deployment of existent and interrelated solutions incorporating both companies technologies. Aegis Spine hence intends to make a many of IMPLANET t Americas sales network on a East Coast of a United States, where a association has small presence. Conversely, IMPLANET will be means to advantage from Aegis Spines estimable approach and surreptitious sales network opposite a rest of North America, capitalizing on new certain clinical formula and a absolute network of opinion leaders;
- In Asia and in Oceania: LK BIOMED will discharge a Jazz® height in serve to a existent product range. The categorical design for both companies will be to jointly dig a Japanese market, a worlds second largest marketplace for medical technologies and one that is fervent for spine innovations in sequence to improved residence a estimable series of aged or aging patients. The dual companies also intend to subsequently dig a Chinese market.
- In Europe: IMPLANET will discharge LK BIOMEDs implants, that element a Jazz® platform, with a transparent idea of apropos a actor of a estimable distance on this continent.
LK BIOMED is really gratified with this partnership with IMPLANET, personality in latest-generation braided implants for treating spine disorders. We resolutely trust that there are estimable synergies between a dual companies on both an handling level, with a disruptive and innovative inlet of a product ranges, and a blurb level, with a particular placement networks, says Lee Seung Joo, CEO of LK BIOMED.
Ludovic Lastennet, CEO of IMPLANET, adds: The hunt for a clever partner of a poignant distance with an innovative product operation that complements a record had been a priority for us in new months. We are gay with this agreement with LK BIOMED, quite as it should capacitate us to significantly intensify a participation in a United States, given a new partners longstanding and successful activity, in Asia, around a healthy participation there and a in-depth believe of these markets specificities, and in Europe, by providing surgeons with an innovative operation of high-end implants that element a possess technology.
This press recover contains forward-looking statements concerning Implanet and a activities. Such brazen looking statements are formed on assumptions that Implanet considers to be reasonable. However, there can be no declaration that a expected events contained in such forward-looking statements will occur. Forward- looking statements are theme to countless risks and uncertainties including a risks set onward in a registration request of Implanet purebred by a French Financial Markets Authority (Autorit des marchs financiers (AMF)) on Apr 26, 2016 underneath series R.16-035 and accessible on a Company’s website (www.implanet-invest.com), and to a growth of mercantile situation, financial markets, and a markets in that Implanet operates. The forward-looking statements contained in this recover are also theme to risks different to Implanet or that Implanet does not cruise element during this time. The fulfilment of all or partial of these risks could lead to tangible results, financial conditions, performances or achievements by Implanet that differ significantly from a results, financial conditions, performances or achievements voiced in such forward-looking statements. This press recover and a information it contains do not consecrate an offer to sell or to allow for, or a questionnaire of an sequence to squeeze or allow for Implanet shares in any country.
Founded in 2007, IMPLANET is a medical record association that manufactures high-quality implants for orthopedic surgery. Its flagship product, a JAZZ® latest-generation implant, aims to provide spinal pathologies requiring vertebral alloy surgery. Protected by 4 families of general patents, JAZZ® has performed 510(k) regulatory clearway from a Food and Drug Administration (FDA) in a United States and a CE mark. IMPLANET employs 48 people and available 2016 sales of 7.8 million. For serve information, greatfully revisit www.implanet.com
Based nearby Bordeaux in France, IMPLANET determined a US auxiliary in Boston in 2013.
IMPLANET is listed on Euronext Growth marketplace in Paris.
Tel.: +33 (5) 57 99 55 55
US Investor Relations
Tel.: +1 (917) 385-2160
Investor Relations France
Tel.: +33 (5) 57 99 55 55
Copyright © 2017 OTC Markets. All Rights Reserved
The above news recover has been supposing by a above association around a OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are only obliged for a correctness of such news releases.